Clinical Trial Update: Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V [Phase 2]

View source ↗

Summary

This clinical trial entry outlines a Phase 2 study to evaluate the efficacy and safety of iptacopan (LNP023) in adults with active lupus nephritis (Class III-IV…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• LNP023 (iptacopan) (iptacopan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lupus Nephritis | Phase 2 | Status: RECRUITING